Advertisement

Search Results

Advertisement



Your search for The ,The matches 34685 pages

Showing 33001 - 33050


lymphoma

Search for Effective Regimens in Elderly Patients With Hodgkin Lymphoma

As the U.S. population continues to age, oncologists will be faced with a growing number of elderly patients with Hodgkin lymphoma, but there is currently no consensus on how to treat this population. Regimens used to treat younger patients have too much toxicity for most older patients, and thus...

Major Depression Is Undertreated in Patients With Cancer

In a Scottish study reported in The Lancet Psychiatry, Walker et al assessed the prevalence and adequacy of treatment of major depression in patients with cancer of different primary sites. The prevalence of major depression ranged from 5.6% in patients with genitourinary cancers to 13.1% in those...

lung cancer

SMaRT Oncology-3 Trial Reports Collaborative Care Program Reduces Major Depression in Patients With Lung Cancer

In the SMaRT Oncology-3 study reported in The Lancet Oncology, Walker et al found that an integrated collaborative treatment program for depression (‘depression care for people with cancer’) was associated with significantly reduced severity of depression compared with usual care in...

Integrated Collaborative Care Program Highly Successful in Treating Major Depression in Patients With Cancer

In a Scottish study (SMaRT Oncology-2) reported in The Lancet, Sharpe, Walker et al found that an integrated collaborative treatment program for depression (‘depression care for people with cancer’) was associated with significantly higher depression response and remission rates...

solid tumors

Second-Line Ramucirumab Plus Paclitaxel Improves Overall Survival in Patients With Advanced Gastric Cancer

The addition of the monoclonal antibody VEGFR-2 antagonist ramucirumab (Cyramza) to paclitaxel led to a statistically significant improvement in median overall survival in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma in a phase III trial, reported Wilke et al in ...

lymphoma

Para-Aortic Lymph Node Radiation Increases Risk of Diabetes in Hodgkin Lymphoma Survivors

Abdominal irradiation for childhood cancer has been associated with increased risk of diabetes. In a Dutch study reported in the Journal of Clinical Oncology, van Nimwegen and colleagues assessed the relationship between infradiaphragm radiotherapy and risk of diabetes in long-term survivors of...

breast cancer

PIK3CA Mutations Associated With Lower Rate of Pathologic Complete Response to Neoadjuvant Anti-HER2 Therapy in Breast Cancer

In a study reported in the Journal of Clinical Oncology, Loibl et al found that PIK3CA mutation was associated with lower pathologic complete response rate in patients with HER2-positive breast cancer receiving trastuzumab (Herceptin), lapatinib (Tykerb), or both in addition to neoadjuvant...

prostate cancer

Male Pattern Baldness at Age 45 May Be Associated With Aggressive Prostate Cancer

In a prospective cohort study in the population of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Zhou et al found that frontal plus moderate vertex baldness at age 45 is associated with increased risk of aggressive prostate cancer. The findings were reported in the...

head and neck cancer

Lymphatic Mapping Agent Receives Orphan Drug Designation for Head and Neck Cancers

Navidea Biopharmaceuticals, Inc, recently announced that technetium 99m tilmanocept (Lymphoseek Injection) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for use in sentinel lymph node detection in patients with cancer of the head and neck. The designation...

Primary Site of Neuroblastoma Tied to Differences in Biologic, Clinical Characteristics, Including Survival

In a study reported in Journal of Clinical Oncology, Vo et al in the International Neuroblastoma Risk Group Project found significant differences in clinical and biologic features of neuroblastoma according to primary tumor site, including poorer survival for adrenal sites of primary disease and...

gynecologic cancers

mTOR Inhibitor Ridaforolimus Shows Activity in Advanced Endometrial Cancer

The oral mTOR inhibitor ridaforolimus was modestly active and reasonably tolerated in women with recurrent or metastatic endometrial cancer, according to the results of a phase II study reported in Gynecologic Oncology. Tsoref et al suggested that it may prove to be an effective therapeutic...

multiple myeloma

Improved Outcomes in Myeloma With High-Dose Melphalan Plus Autologous Transplant and Lenalidomide Maintenance

In a phase III trial reported in The New England Journal of Medicine, Palumbo et al found that consolidation therapy with high-dose melphalan plus autologous stem cell transplantation improved progression-free survival and overall survival compared with melphalan/prednisone/lenalidomide (Revlimid)...

colorectal cancer

Improved Survival with Adjuvant FOLFOX vs Fluorouracil/Leucovorin After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

In a Korean phase II trial reported in The Lancet Oncology, Hong et al found that adjuvant FOLFOX (oxaliplatin, fluorouracil [5-FU], leucovorin) prolonged progression-free survival and overall survival vs 5-FU/leucovorin in patients with locally advanced rectal cancer who had received neoadjuvant...

colorectal cancer

Long-Term Colorectal Cancer Mortality After Removal of Adenomas

There are few data available on long-term risk of colorectal cancer mortality after adenoma removal. In a Norwegian study reported in The New England Journal of Medicine, Løberg et al found that patients who had low-risk adenomas removed had lower colorectal cancer mortality risk and those...

lung cancer

ASTRO: Analysis Finds Select Group of Stage IV Lung Cancer Patient Population Achieves Long-Term Survival After Aggressive Treatment

A large, international analysis of patients with stage IV non–small cell lung cancer (NSCLC) indicates that a patient’s overall survival rate can be related to factors including the timing of when metastases develop and lymph node involvement, and that aggressive treatment for low-risk...

lung cancer

ASTRO: Good Primary Tumor Control, Positive 5-Year Survival Rates for Lung Cancer Patients Who Receive Stereotactic Body Radiation Therapy

Patients with inoperable, early-stage lung cancer who receive stereotactic body radiation therapy have a 5-year survival rate of 40%, according to long-term results presented at the American Society for Radiation Oncology’s (ASTRO) 56th Annual Meeting (Abstract 56). Such a positive survival...

prostate cancer

ASTRO: Long-Term Androgen-Deprivation Therapy Plus High-Dose Radiation Therapy Improves Biochemical Control and Survival Rates in Prostate Cancer

Prostate cancer patients who receive high-dose radiation therapy followed by a longer period of androgen-deprivation therapy have higher 5-year biochemical disease–free survival and overall survival rates compared to patients who receive high-dose radiation therapy and a shorter duration of...

gynecologic cancers

Adding Cediranib to Olaparib Improves Progression-Free Survival and Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer

In a randomized phase II trial reported in The Lancet Oncology, Liu et al found a significant improvement in progression-free survival and an increase in toxicity with the addition of the antiangiogenic agent cediranib (VEGFR-1,-2,-3 inhibitor) to the PARP inhibitor olaparib in women with recurrent ...

prostate cancer

Baseline Results of the UK Phase III ProtecT Trial of Active Monitoring, Radical Prostatectomy, or Radiotherapy for Localized Prostate Cancer

The UK phase III ProtecT trial is comparing the effectiveness of active monitoring, radical prostatectomy, and radiotherapy in men with localized prostate cancer. Lane et al have provided baseline results of the trial in an article in The Lancet Oncology. Study Details In the trial, men aged 50...

lung cancer

Study Identifies Two Novel ALK Mutations Causing Lung Cancer Resistance to ALK Inhibitors

In a recent study investigating alectinib resistance in ALK-positive lung cancers, researchers identified two novel ALK mutations that are sensitive to ceritinib (Zykadia), a next-generation ALK tyrosine kinase inhibitor approved by the FDA earlier this year for advanced non–small cell lung...

lymphoma

Anti-CD19 CAR T-Cell Treatment Effective in Chemotherapy-Refractory B-Cell Malignancies

In a study reported in the Journal of Clinical Oncology, Kochenderfer et al found that single infusions of autologous T cells expressing an anti-CD19 chimeric antigen receptor (CAR) produced responses in nearly all patients with chemotherapy-refractory CD19-positive B-cell malignancies, including...

breast cancer
issues in oncology

Little Molecular Difference and No Prognostic Effect of Clinical HER2 Status in Context of Intrinsic Breast Cancer Subtypes

In a study reported in the Journal of the National Cancer Institute, Prat et al found that there was little difference in downstream gene or protein expression according to intrinsic breast cancer subtypes among clinical HER2-positive vs -negative breast cancers and that clinical HER2 status did...

breast cancer

ASTRO: Radiation Therapy Does Not Increase Risk of Lymphedema in Node-Negative Breast Cancer

A secondary analysis of the National Surgical Adjuvant Breast and Bowel Project B-32 trial indicates that radiation therapy does not increase the incidence of lymphedema in patients with node-negative breast cancer, according to research presented at the American Society for Radiation...

AACR’s 2014 Cancer Progress Report Stresses Research Advances and More Federal Funding

The American Association for Cancer Research (AACR) released its 2014 Cancer Progress Report today, which highlights the quickening pace of drug development and approval, especially in molecularly targeted agents that are leading to increased numbers of cancer survivors. However, the report also...

issues in oncology
gastroesophageal cancer

ASTRO: Pretreatment Serum Levels of VEGF-A and TGF-β1 Predictive of Outcomes in Esophageal Cancer

Serum levels of VEGF-A and TGF-β1 may be helpful in tailoring neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma, according to research presented at the American Society for Radiation Oncology’s (ASTRO) 56th Annual Meeting (Abstract 10). Results of...

gastroesophageal cancer

ASTRO: Radiation Therapy Alone vs Chemoradiotherapy for Reducing Dysphagia in Advanced Esophageal Cancer

Radiation therapy alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as radiation therapy combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented at the American Society for Radiation...

prostate cancer

ASTRO: Shorter Course of Androgen-Deprivation Therapy Yields Improved Quality of Life for High-Risk Prostate Cancer Patients

Patients with high-risk prostate cancer who received radiation therapy and an 18-month course of androgen-deprivation therapy recovered a normal testosterone level in a shorter amount of time compared to those who received a 36-month course of androgen-deprivation therapy. The shorter course of...

lymphoma

ASTRO: Radiation Therapy Improves Survival in Patients With Early-Stage Hodgkin Lymphoma

Patients with stage I and II Hodgkin lymphoma who received consolidated radiation experienced improved 10-year survival rates, according to research presented at the American Society for Radiation Oncology (ASTRO) 56th Annual Meeting (Abstract CT-08). The 10-year survival rate for patients who...

leukemia

Genomic Analysis Reveals That a High-Risk Leukemia Subtype Becomes More Common With Age

More than one-quarter of young adults with the most common form of acute lymphoblastic leukemia have a high-risk subtype with a poor prognosis and may benefit from drugs widely used to treat other types of leukemia that are more common in adults, according to multi-institutional research led by St. ...

breast cancer

No Significant Progression-Free Survival Benefit of Adding Ramucirumab to First-Line Docetaxel in Advanced HER2-Negative Breast Cancer

In the phase III ROSE/TRIO-12 trial, reported in the Journal of Clinical Oncology, Mackey et al found no significant improvement in investigator-assessed progression-free survival by adding the antiangiogenic VEGFR-2 inhibitor ramucirumab (Cyramza) to first-line docetaxel in women with...

skin cancer

Increased Risk of Melanoma in Flight-Based Occupations

Airline pilots and cabin crew are occupationally exposed to higher levels of cosmic and ultraviolet radiation. In a meta-analysis reported in JAMA Dermatology, Sanlorenzo et al found that these people have a more than twofold greater risk of melanoma compared with the general population. Increased ...

colorectal cancer
issues in oncology

Modeling Study Critical of Intensive Colonoscopy Screening in Medicare Population

A modeling study reported in JAMA Internal Medicine by van Hees and colleagues showed that  colonoscopy screening at intervals shorter than 10 years or continuing past 75 years of age in the Medicare population is associated with a reduced net health benefit from a societal perspective. Study ...

kidney cancer
kidney cancer

Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses Produce Similar Rates of Local Tumor Recurrence

Recurrence-free survival rates were similar for patients with cT1 renal masses who underwent partial nephrectomy or percutaneous cryoablation, according to the results of a retrospective trial reported by Thompson et al in European Urology. However, metastases-free survival was superior for...

prostate cancer

FDA Approves New Indication for Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration (FDA) has approved a new indication for the use of enzalutamide (Xtandi) capsules to treat patients with metastatic castration-resistant prostate cancer. The new indication is for men with metastatic castration-resistant prostate cancer who have not received...

breast cancer

Modeling Study Indicates Little Survival Difference With Contralateral Prophylactic Mastectomy in Breast Cancer Without BRCA Mutation

In a study reported in the Journal of the National Cancer Institute, Portschy et al found an absolute 20-year overall survival difference of < 1% with contralateral prophylactic mastectomy in women with stage I or II breast cancer without BRCA mutation. The authors had hypothesized that the...

breast cancer

Racial/Ethnic Barriers to Breast Reconstruction After Mastectomy for Breast Cancer

In a study reported in JAMA Surgery, Morrow et al found that breast reconstruction after mastectomy for breast cancer largely reflects patient demand, with the majority of women being satisfied with the decision-making process. However, black women were significantly less likely to have...

pancreatic cancer

Baseline Vitamin D Not Associated With Survival in Patients With Advanced Pancreatic Cancer in CALGB 80303/Alliance Trial

Preclinical data indicate a role of vitamin D metabolism in pancreatic tumor development. In a study reported in the Journal of the National Cancer Institute, Van Loon et al found that baseline serum 25-hydroxyvitamin D (25[OH]D) levels were not associated with progression-free survival or overall...

lung cancer
issues in oncology

ALK Rearrangements Are Associated With Improved Outcomes in Patients With Non‒Small Cell Lung Cancer and Brain Metastases

Compared with mutations in EGFR, KRAS, or with patients with no known mutations, ALK rearrangements were independently associated with improved survival outcomes in patients with non–small cell lung cancer (NSCLC) who received radiotherapy for brain metastases, according to the results of a...

head and neck cancer

No Benefit of Adding Cetuximab to Cisplatin and Accelerated Radiotherapy in Stage III or IV Head and Neck Carcinoma

Use of cisplatin or cetuximab (Erbitux) with radiotherapy improves overall survival in stage III or IV head and neck carcinoma, and adding cetuximab to platinum therapy improves overall survival in metastatic disease. In the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial reported in...

gynecologic cancers

Radiation Therapy With Concurrent Chemotherapy After Surgery Is an Effective Treatment for High-Risk Endometrial Cancer

Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for high-risk endometrial cancer, according to a study reported by Cho et al in the International Journal of Radiation Oncology • Biology • Physics   Endometrial...

prostate cancer

ASCO and Cancer Care Ontario Release Clinical Practice Guideline for Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer

The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline is reported by Basch et al in the Journal of...

hepatobiliary cancer

Phase II Trial Shows Overall Survival Benefit With VT-122 Plus Sorafenib in Advanced Hepatocellular Carcinoma

The investigational agent VT-122 appeared to benefit survival when combined with sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma, according to data presented at the 8th Annual International Liver Cancer Association Conference in Kyoto, Japan. Researchers reported an 11-month...

breast cancer

Less Frequent Use of Sentinel Lymph Node Biopsy and Higher Risk of Lymphedema in Black Women With Breast Cancer in Medicare Population

In a retrospective study reported in JAMA Surgery, Black et al found that the sentinel lymph node biopsy rate was lower and risk for lymphedema higher in black vs white women with early-stage breast cancer in the Medicare population. Study Details The study used the Surveillance, Epidemiology,...

gynecologic cancers

Olaparib Tablet Found Safe and Effective in Heavily Pretreated Patients With Ovarian Cancer

A phase Ib clinical trial of the tablet form of olaparib, a PARP inhibitor, in combination with paclitaxel and carboplatin chemotherapy in heavily pretreated patients with advanced-stage ovarian cancer finds the drug to be safe and effective, especially in those women with BRCA gene mutations. The...

lymphoma

No Significant Difference in Time to Treatment Failure With Rituximab Retreatment vs Maintenance in Low-Tumor-Burden Follicular Lymphoma

Maintenance rituximab (Rituxan) has been shown to improve progression-free survival vs observation in low-tumor-burden follicular lymphoma. In the Eastern Cooperative Oncology Group (ECOG) E4402 Trial (RESORT), reported in the Journal of Clinical Oncology, Kahl et al found no significant difference ...

lung cancer
issues in oncology

National Lung Screening Trial Analysis Finds Low-Dose CT Screening Identifies More Lung Cancers in Older vs Younger Participants

Findings from the National Lung Screening Trial (NLST) showed that screening high-risk individuals (smoking history of ≥ 30 pack-years) aged 55 to 74 with low-dose computed tomography (CT) vs chest radiography reduced lung cancer mortality. Following the study results, the U.S. Preventive...

breast cancer

Breast-Conserving Therapy Shows Survival Benefit Over Mastectomy in Patients With Early-Stage Hormone Receptor–Positive Disease

When factoring in what is now known about breast cancer biology and heterogeneity, breast-conserving therapy may offer a greater survival benefit over mastectomy to women with early-stage, hormone receptor–positive disease, according to research from The University of Texas MD Anderson Cancer ...

breast cancer

Once-Weekly Breast Irradiation Following Lumpectomy Results in Better Compliance, Lower Costs, and Comparable Cosmetic Outcomes vs Daily Treatment

An experimental regimen of once-weekly breast irradiation following lumpectomy provides more convenience to patients at a lower cost, results in better completion rates of prescribed radiation treatment, and produces cosmetic outcomes comparable to the current standard of daily radiation. These...

breast cancer
issues in oncology

Disparities Persist in Early-Stage Breast Cancer Treatment

Despite its acceptance as standard of care for early-stage breast cancer almost 25 years ago, barriers still exist that preclude patients from receiving breast-conserving therapy, with some still opting for a mastectomy, according to research from The University of Texas MD Anderson Cancer Center....

breast cancer

Novel Immunotherapy Vaccine Decreases Recurrence in HER2-Positive Breast Cancer Patients

A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug. These findings were presented at the 2014 Breast...

Advertisement

Advertisement




Advertisement